There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VistaGen Therapeutics (VTGN – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish sentiments.
VistaGen Therapeutics (VTGN)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics. The company’s shares closed last Wednesday at $3.15, close to its 52-week low of $1.62.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VistaGen Therapeutics.
See the top stocks recommended by analysts >>
Rhythm Pharmaceuticals (RYTM)
Goldman Sachs analyst Corinne Jenkins reiterated a Buy rating on Rhythm Pharmaceuticals today. The company’s shares closed last Wednesday at $22.65.
According to TipRanks.com, Jenkins is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rhythm Pharmaceuticals with a $35.60 average price target, representing a 58.4% upside. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VTGN:
- Vistagen says PH80 showed statistically significant improvement versus placebo
- Biotech Alert: Searches spiking for these stocks today
- Maxim bullish on Vistagen amid time-limited partnership with Fuji Pharma
- Vistagen, Fuji in deal for potential license for hot flash nasal spray, in Japan
- Largest borrow rate increases among liquid names
